NMDA receptor-expressing neurons represent a fundamental population in the central nervous system, characterized by their expression of N-methyl-D-aspartate (NMDA) type glutamate receptors. These neurons play critical roles in synaptic transmission, plasticity, and survival. NMDA receptors are ionotropic glutamate receptors that require co-activation by glutamate and glycine, with voltage-dependent magnesium block removal as a key feature enabling calcium influx during synaptic activity.
NMDA receptors are heteromeric complexes composed of GluN1 (GRIN1) subunits combined with GluN2 (GRIN2A-D) and/or GluN3 (GRIN3A-B) subunits. The subunit composition dramatically influences receptor properties:
The relative abundance of GluN2A versus GluN2B subunits shifts in neurodegenerative diseases, with a shift toward GluN2B dominance associated with increased excit vulnerability [1].
A critical distinction exists between synaptic and extrasynaptic NMDA receptors that determines neuronal outcomes:
Extrasynaptic NMDAR hyperactivity has been documented in early-stage Alzheimer's disease, where it contributes to dendritic spine loss and memory impairment [2]. The balance between synaptic and extrasynaptic signaling is disrupted in neurodegeneration.
Excessive calcium influx through NMDA receptors initiates excitotoxic cascades:
This calcium dysregulation is particularly relevant in Huntington's disease, where mutant huntingtin protein enhances NMDAR-mediated calcium influx [3].
In Alzheimer's disease, amyloid-beta (Aβ) oligomers interact with NMDA receptors, disrupting normal function:
Memantine, an NMDA receptor antagonist, has been developed to selectively block extrasynaptic NMDARs while preserving synaptic function [4].
NMDA receptors contribute to dopaminergic neuron degeneration in Parkinson's disease through multiple mechanisms:
Targeting specific NMDAR subunits (particularly GluN2B) has been explored as a neuroprotective strategy [5].
Pharmacological modulation of NMDA receptors remains a key therapeutic target:
Challenges include maintaining sufficient receptor blockade for neuroprotection while avoiding cognitive side effects from broad NMDAR inhibition.